ALGO Increases by 0.37% as Biotech Experiments Progress and Markets Fluctuate

On November 4, 2025, ALGO experienced a 0.37% increase over the previous 24 hours, reaching a value of $0.1605. This comes despite the token falling 7.64% over the last week and dropping 51.93% over the past year. These price changes mirror the overall trends in the biotech and pharmaceutical sectors, as companies gear up for significant data releases at the ASH Annual Meeting. While ALGO has suffered notable long-term losses, the recent short-term rise could indicate a resurgence of investor enthusiasm in the wake of major sector news.

Allogene Therapeutics, a company specializing in allogeneic CAR T-cell therapies, revealed it will present a Trial-in-Progress (TIP) poster for its pivotal Phase 2 ALPHA3 study on cemacabtagene ansegedleucel (cema-cel) at the 2025 American Society of Hematology (ASH) Annual Meeting. This trial aims to assess cema-cel as a first-line consolidation treatment for large B-cell lymphoma (LBCL) patients who remain MRD positive after standard therapy. The open-label, randomized study compares cema-cel with lymphodepletion to standard monitoring. The poster will showcase the study’s innovative approach, including a futility analysis anticipated in the first half of 2026. This development highlights the increasing momentum in CAR T-cell therapy and could shape investor sentiment toward the broader biotech industry.

Dr. John Burke will present the poster on December 7, focusing on the trial’s potential to transform treatment standards by providing an “off-the-shelf” cell therapy solution. Since the FDA granted cema-cel Regenerative Medicine Advanced Therapy (RMAT) status in 2022, the trial’s structure positions

as a leading force in the development of MRD-targeted therapies. Such advancements may be seen by investors as sector catalysts, possibly impacting the performance of assets such as ALGO.

Geron Corporation also shared important news, announcing that five of its presentations were accepted for the ASH 2025 Annual Meeting. These include one oral and four poster sessions centered on RYTELO® (imetelstat). The presentations will cover both clinical and translational findings from studies in myeloid blood cancers, with an emphasis on long-term survival data and biomarker research. Geron’s CEO highlighted the increasing scientific interest in imetelstat and its promise for providing lasting benefits to patients. These developments further demonstrate the sector’s robust pipeline and may boost overall investor confidence.